ישראל -
עברית -
Ministry of Health
מווקס תמיסה
vitamed pharmaceutical industries ltd - bromhexine hydrochloride - תמיסה - bromhexine hydrochloride 2.00 mg/ml - bromhexine - bromhexine - bronchial mucolytic. it can also be given by inhalation as an aerosol solution.
ישראל -
עברית -
Ministry of Health
אפידיולקס
neopharm ltd, israel - cannabidiol - תמיסה - cannabidiol 100 mg / 1 ml - cannabidiol
ישראל -
עברית -
Ministry of Health
אילאריס 150 מגמל תמיסה להזרקה
novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab
ישראל -
עברית -
Ministry of Health
המליברה 150 מגמל
roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 150 mg / 1 ml - emicizumab
ישראל -
עברית -
Ministry of Health
המליברה 30 מגמל
roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 30 mg / 1 ml - emicizumab
ישראל -
עברית -
Ministry of Health
פרבליפ 10
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin
ישראל -
עברית -
Ministry of Health
פאפאוורין טבע להזרקה
teva israel ltd - papaverine hydrochloride - תמיסה להזרקה - papaverine hydrochloride 40 mg / 2 ml - papaverine - papaverine - antispasmodic in visceral spasm, e.g. gastrointestinal colic, biliary and urinary tract spasms. peripheral vascular disease with vasospastic element. vascular spasm associated with acute myocardial infarcion, angina pectoris, peripheral and pulmonary embolism.
ישראל -
עברית -
Ministry of Health
זלבוראף
roche pharmaceuticals (israel) ltd - vemurafenib - טבליות מצופות פילם - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.
ישראל -
עברית -
Ministry of Health
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.